Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates.

UDP-glucuronosyltransferase 1A1 (UGT1A1) is a polymorphic enzyme responsible for the glucuronidation of structurally diverse drugs, non-drug xenobiotics and endogenous compounds (e.g. bilirubin). Thus, definition of UGT1A1 substrate and inhibitor selectivities and binding affinities assumes importance for the identification of compounds whose elimination may be impaired in subjects with variant genotypes, and for the prediction of potentially inhibitory interactions involving xenobiotics and endogenous compounds metabolized by UGT1A1. We report the generation of two- and three-dimensional (2D and 3D) quantitative structure activity relationships (QSAR) and pharmacophore models for 23 known UGT1A1 substrates with diverse structure and binding affinity. Initially, a simple procedure was developed to determine apparent inhibition constants (Ki,app) for these compounds. Eighteen substrates were subsequently used to construct models and the remaining five to validate the predictive ability of the models. Three different models were constructed: (i) three feature pharmacophore model able to predict the Ki,app on the basis of the degree to which a substrate can fit to the arrangement of 3D features (r2 = 0.87, Ki,app for all five test substrates predicted within log unit); (ii) 3D-QSAR using a 'common features' pharmacophore to align the substrates (r2 = 0.71, Ki,app for four out of five test substrates predicted within one log unit); (iii) 2D-QSAR constructed with six chemical descriptors (r2 = 0.92, Ki,app of all five test substrates predicted within one log unit). The common features pharmacophore demonstrated the importance of two hydrophobic domains separated from the glucuronidation site by 4 A and 7 A, respectively. These models, which represent the first generalized predictive models for a UGT isoform, complement each other and are an important first step towards computer based (in silico) models of UGT1A1 for high throughput prediction of metabolism.

[1]  P. Sprague Automated chemical hypothesis generation and database searching with Catalyst , 1995 .

[2]  David J. Livingstone,et al.  The Characterization of Chemical Structures Using Molecular Properties. A Survey , 2000, J. Chem. Inf. Comput. Sci..

[3]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[4]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[5]  K H Kim,et al.  Quantitative structure-activity relationships of the metabolism of drugs by uridine diphosphate glucuronosyltransferase. , 1991, Journal of pharmaceutical sciences.

[6]  S. Ekins,et al.  Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.

[7]  Martyn G. Ford,et al.  Unsupervised Forward Selection: A Method for Eliminating Redundant Variables , 2000, J. Chem. Inf. Comput. Sci..

[8]  J. Crawford,et al.  Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. , 1991, The Journal of biological chemistry.

[9]  B. Burchell,et al.  Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. , 1994, The Biochemical journal.

[10]  W. Richards,et al.  Self-organizing molecular field analysis: a tool for structure-activity studies. , 1999, Journal of medicinal chemistry.

[11]  M. Green,et al.  Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[12]  S. Ekins,et al.  Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.

[13]  J. Miners,et al.  Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. , 2002, Toxicology.

[14]  S. Wold,et al.  The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .

[15]  S. Ekins,et al.  Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[16]  J. Miners,et al.  Drug glucuronidation in humans. , 1991, Pharmacology & therapeutics.

[17]  G Klebe,et al.  Docking ligands onto binding site representations derived from proteins built by homology modelling. , 2001, Journal of molecular biology.

[18]  S. Ghosh,et al.  Genetic lesions of bilirubin uridine‐diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler‐Najjar and Gilbert syndromes: Correlation of genotype to phenotype , 2000, Human mutation.

[19]  P. Mackenzie,et al.  Structural and functional studies of UDP-glucuronosyltransferases. , 1999, Drug metabolism reviews.

[20]  D W Nebert,et al.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.

[21]  S. Ekins,et al.  Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.

[22]  E Holmes,et al.  Quantitative structure-metabolism relationships (QSMR) using computational chemistry: pattern recognition analysis and statistical prediction of phase II conjugation reactions of substituted benzoic acids in the rat. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  R. Green,et al.  Mechanism of indinavir-induced hyperbilirubinemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Spector,et al.  Glucuronidation of 3'-azido-3'-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. , 1991, Biochemical pharmacology.

[25]  M. Green,et al.  The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. , 1996, Archives of biochemistry and biophysics.

[26]  A. Karim The pharmacokinetics of Norpace. , 1975, Angiology.

[27]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[28]  C. Ioannides,et al.  An improved and updated version of the compact procedure for the evaluation of P450-mediated chemical activation. , 1998, Drug metabolism reviews.

[29]  INHIBITION OF BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE : A COMPARATIVE MOLECULAR FIELD ANALYSIS (COMFA) , 1996 .

[30]  T. Visser,et al.  Glucuronidation of thyroid hormone by human bilirubin and phenol UDP‐glucuronyltransferase isoenzymes , 1993, FEBS letters.

[31]  B. Burchell,et al.  Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. , 1993, Molecular pharmacology.

[32]  A. Good,et al.  Structure-activity relationships from molecular similarity matrices. , 1993, Journal of medicinal chemistry.

[33]  Roberto Todeschini,et al.  Handbook of Molecular Descriptors , 2002 .

[34]  J. Miners,et al.  Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. , 1988, Biochemical pharmacology.

[35]  Andrew Smellie,et al.  Identification of Common Functional Configurations Among Molecules , 1996, J. Chem. Inf. Comput. Sci..

[36]  M. Ratain,et al.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.

[37]  J. Jones,et al.  Mechanistic studies of uridine diphosphate glucuronosyltransferase. , 1994, Chemico-biological interactions.

[38]  H. Kubinyi Comparative Molecular Field Analysis (CoMFA) , 2002 .

[39]  R. Tukey,et al.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.

[40]  A. Cohen,et al.  The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome). , 1989, British journal of clinical pharmacology.